Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22849567 | 0.83 | HTR2C (0.50) | BACE1ESR2HTR1AHTR7HTR2C | |
| SCHEMBL11197977 | 0.80 | ESR2 (0.44) | BACE1ESR2 | |
| SCHEMBL11199923 | 0.78 | ESR2 (0.43) | BACE1ESR2 | |
| SCHEMBL14337236 | 0.78 | FAAH (0.34) | ESR2SLC6A4HTR1AHTR7HTR2C | |
| SCHEMBL14336823 | 0.78 | KDM1A (0.31) | ESR2HTR2C | |
| SCHEMBL18517325 | 0.77 | BACE1 (0.32) | BACE1ESR2 | |
| SCHEMBL15180956 | 0.76 | CCR2 (0.34) | CCR2BACE1ESR2 | |
| SCHEMBL15180966 | 0.75 | BACE1 (0.31) | BACE1 | |
| SCHEMBL10930465 | 0.75 | SIGMAR1 (0.39) | CCR2BACE1ESR2HTR2C | |
| SCHEMBL10014156 | 0.74 | BACE1 (0.30) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436028-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | CCR2 2307/4885BACE1 756/4885ESR2 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.